US FDA ‘Brainstorms’ For Ways To Resume Pre-Pandemic Inspection Cadence
The FDA's drug inspections director discusses trends and challenges in remarks at a Georgia GMP conference, while declining to share specific ideas generated in last week’s agency brainstorming session.
You may also be interested in...
Many US COVID-19 Guidances Set To Sunset With Emergency Declaration
But some, including some related to inspections and master protocols, will remain in effect to allow for revisions or a transition out of the pandemic posture.
Transparency Looms Large In US FDA’s Next-Pandemic Legislative Agenda
Agency’s proposals for pandemic preparedness reauthorization would build on CARES Act provisions to gain greater visibility into global pharmaceutical supply chains, while also seeking deeper understanding of manufacturing quality management activities. Also included in FY 2024 budget request: long-sought drug destruction and drug recall authorities.
For Reauthoring Preparedness Law, Congress Needs Advice On Next Public Health Emergency
House Energy and Commerce members seek input as appropriate mix of incentives for next-generation, public-private ventures remains elusive.